title: [Experimental study of protective effects of hepatotrophic factors on hepatic functions in rats with portal hypertension after portacaval shunt].
abstract: OBJECTIVE
  To investigate the protective effects of hepatotrophic factors (hepatocyte growth-promoting factor and insulin) on hepatic functions and pathology in rats with portal hypertension after portacaval shunt.
  
  
  METHODS
  The rats of hepatic cirrhosis with portal hypertension were randomly assigned into 1 control group, 1 model group and 4 treatment groups (NS, HGF, INS, HGF + INS). An end-side portacaval shunt was performed in the treatment group. The hepatotrophic factors were respectively injected into portal vein. After treatment, the serum levels of ALT (alanine aminotransferase), AST (aspartate aminotransferase), HA (hyaluronic acid) and LN (laminin) were determined by radioimmunoassay. And then according to the hematoxylin and eosin (H&E) staining results, the tissue slides were prepared.
  
  
  RESULTS
  The serum levels of ALT (30.13 ± 4.12 U/L), AST (133.75 ± 21.18 U/L), HA (322.49 ± 52.33 µg/L) and LN (23.89 ± 5.03 µg/L) were lower in the HGF + INS group than those in the NS group (all P < 0.01); the scores of hepatic fibrosis stages (1.63 ± 0.74) and collagen semiquantitative of Masson stain (10.17 ± 1.14 × 10(-2)) were significantly reduced in the HGF + INS group than those in the NS group (all P < 0.01).
  
  
  CONCLUSIONS
  The injection of hepatotrophic factors through portal vein after portacaval shunt can improve hepatic functions, reduce the damages of hepatocyte and improve the degree of hepatic fibrosis.
authors.affiliation: Department of General Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Jiang
authors.forename: Jing-Ming
authors.initials: JM
authors.lastname: Zhao
authors.forename: Zhong-Tao
authors.initials: ZT
authors.lastname: Zhang
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005355:Fibrosis; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D006975:Hypertension, Portal / Q000503:physiopathology / Q000601:surgery*; D007328:Insulin / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D011167:Portacaval Shunt, Surgical; D011169:Portal Vein; D011184:Postoperative Period; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D007328:Insulin; D017228:Hepatocyte Growth Factor